Board of Directors

Eric Reiman, M.D.

Chair

Dr. Eric Reiman joined the Flinn Foundation Board of Directors in 1999 and was elected chair in 2023. He previously had served as secretary since 2008. He is an independent researcher, Senior Advisor and collaborator at the Banner Alzheimer’s Institutes, which include Banner Alzheimer’s and Banner Sun Health Research Institutes, and one of the leaders of its Alzheimer’s Prevention Initiative. He is Professor of Psychiatry at the University of Arizona College of Medicine-Phoenix, University Professor of Neuroscience at Arizona State University, Clinical Professor at the Translational Genomics Research Institute, and director of the NIH-sponsored Arizona Alzheimer’s Disease Research Center.

Dr. Reiman was the founding CEO of Banner Alzheimer’s Institutes, where he and his colleagues grew the organization into an internationally recognized leader in the scientific and clinical fight against Alzheimer’s, founding director of the Arizona Alzheimer’s Consortium and its NIH-sponsored Arizona Alzheimer’s Consortium, which became a leading model of statewide research collaboration, and founding Clinical Director of the Neurogenomics Division at TGen. After nearly four decades at Banner and two decades leading Banner Alzheimer’s Institute, he left Banner and his leadership role in the Arizona Alzheimer’s Consortium in fall 2026 to work independently, deepen his focus on Alzheimer’s prevention, and spend more time with his family. He will continue to work with organizations inside and outside Arizona to address their shared goals together.

He is also a co-founder and advisor to ALZPath, a startup company that aims to advance the role of blood tests in Alzheimer’s disease research and care.

A psychiatrist and brain-imaging researcher by background, Dr. Reiman’s interests include brain imaging, blood-based biomarkers, APOE and genomics research, the unusually early detection, tracking, and study of Alzheimer’s disease, the accelerated evaluation of Alzheimer’s prevention therapies, and new models of research collaboration and clinical care. He has been an author of more than 800 publications, a principal investigator of several large research NIH grants and other state and foundation grants and contracts, a former member of the National Advisory Council on Aging, and a recipient of the Potamkin Prize for his pioneering contributions to the early detection, prevention, and study of Alzheimer’s disease. His overarching goal is to find and support the approval, affordability, and widespread availability of effective Alzheimer’s prevention therapies within the next few years.

Dr. Reiman graduated from Duke University, studied at Oxford University, and returned to Duke for his medical degree and the first three years of his psychiatry residency. Before moving to Arizona, he completed his psychiatry residency and research fellowship at the Washington University School of Medicine in St. Louis, where he was a faculty member and embarked on a research career in the lab that invented positron emission tomography (PET).